HIV drug regimens are hard to maintain
May 1st 2001HIV-positive individuals find it difficult to comply with their drug regimens, according to data from "The Survey on Treatment Adherence by HIV-positive People," a confidential survey conducted by Chicago-based Savitz Research and underwritten by GlaxoSmithKline, Research Triangle Park, NC.
Healthcare spending growth stays low
May 1st 2001Spending for all healthcare in the United States topped $1.2 trillion in 1999, up 5.6% from 1998, but continued a six-year trend of growth below 6%, according to a report by the Health Care Financing Administration. HCFA projections of future healthcare spending predict faster growth over the next decade, although not at the high rates of the 1980s and early 1990s.
Pfizer finds success with Vista Rx program
May 1st 2001In a profession in which success is often driven by long hours, the concept of cutting back to a part-time job may seem foreign, but a reduction in hours can sometimes be necessary for even the most dedicated reps. New York-based Pfizer Inc. has responded to this need by creating its part-time field sales force, Vista Rx. Launched in April 1999 as a pilot program with 70 reps, Vista Rx allows sales representatives to work 60% of a full-time schedule while retaining the benefits and privileges of full-time employees, making it the first of its kind in the industry.
Study shows gender differences in progression of HIV to AIDS
May 1st 2001During the first years of HIV infection, women have significantly lower amounts of the virus in their blood than men, according to one of the largest studies ever to examine gender-specific differences in HIV infection. Despite their lower initial viral levels, women suffer the loss of immune cells and develop AIDS just as swiftly as men. The findings, reported in The New England Journal of Medicine (vol. 344, no. 10), lend further support to recent changes in the criteria used to help doctors tailor anti-HIV drug therapy to delay the onset of AIDS.
Global pharma sales top $300 billion
May 1st 2001Westport, CT-based IMS Health has released data from its annual "World Review" report showing that audited global pharmaceutical sales grew 10% in 2000 to $317.2 billion, up from $295.9 billion in 1999. "The IMS Health World Review" tracks actual sales of approximately 90% of all prescription drugs and certain over-the-counter products in more than 60 countries. Proprietary data projection methodologies are used to estimate total global pharmaceutical sales, which grew to $354 billion in 2000.
Spending on consumer ads up in 2000
May 1st 2001Pharmaceutical manufacturers spent $1.9 billion on direct-to-consumer advertising of prescription drugs between January and September 2000, the same amount spent in all of 1999, according to Newtown, PA-based Scott-Levin's "Direct-to-Consumer Advertising Audit." The audit, which surveyed over 4,000 consumers and 3,000 physicians, found that two major therapeutic classes - antihistamines and COX-2 inhibitors - generated 20% ($390 million) of advertising expenditures in the first nine months of 2000.
Study shows Rx drug misuse costs billions
May 1st 2001A new study released in the Journal of the American Pharmaceutical Association (vol. 41, no. 2) estimates that drug misuse costs the economy more than $177 billion each year. And, according to the study, the estimated number of patient deaths resulting from misuse of prescription drugs has increased from 198,000 in 1995 to 218,000 in 2000.
Anesthesiologists report drug shortages
May 1st 2001In an effort to address the declining flow of much-needed medications used during surgery, the American Society of Anesthesiologists is calling on federal regulators and pharmaceutical industry leaders to take action quickly to end the nationwide shortage of anesthetic agents.
Reforms suggested in IOM's second report
May 1st 2001The Institute of Medicine of the Washington-based National Academy of Sciences has released "Crossing the Quality Chasm: A New System for the 21st Century," a follow-up to its earlier report, "To Err is Human." While "To Err is Human" concentrated on the issue of patient safety, the new report offers suggestions for wider healthcare reform.
Annual Reports: Size Doesn't Matter
April 1st 2001Bagsvaerd, Denmark-Niche players with good exposure to US markets are showing strong growth, bucking the notion that size is everything in the pharmaceutical industry. And, if it is true that the industry is recession-proof, that situation is unlikely to change, even in the event of a US downturn.
Partnerships: Bargaining Biotechs
April 1st 2001Uniondale, New York, USA-Thirty-eight companies submitted proposals to develop OSI-774, OSI Pharmaceuticals' lead cancer candidate, making it the most sought-after compound of 2000. The statistic was revealed with some satisfaction by Myrtle Potter, chief operating officer of Genentech, the joint winner-along with Roche, its majority stockholder-at the Economist Conferences' annual pharmaceuticals conference.